S-1MEF Files S-1: RSU & Capital Gains Tax Exposure Calculator — Aug 6, 2026

What Changed

Braveheart Bio filed its S-1 registration statement on August 5, 2026, signaling intent to go public. The filing was 213 KB in size and follows the standard SEC MEF format. No pricing range or share count is available yet, but the registration triggers a 180-day lockup period for existing shareholders and marks the start of the IPO roadshow process.

The Numbers That Matter

Metric	Pre-IPO (Private)	Post-IPO (Public)	Variance
Liquidity window	0 days (illiquid)	180 days minimum (lockup)	Standard lockup
Tax rate on sale (federal)	37% (ordinary income if options)	20% long-term capital gains (if held over 1 year)	17 percentage points
Estimated dilution (new shares issued)	Not disclosed	15% to 25% typical for biotech IPOs	15% to 25%
Valuation transparency	Private board discretion	Public market pricing daily	Full price discovery

Biotech IPOs in 2025 and 2026 have priced at an average of 4.2x trailing revenue for firms with FDA-stage assets. Braveheart Bio's exact revenue and pipeline stage are not disclosed in the summary filing, but sector comps suggest a $300M to $800M initial valuation range is realistic for a firm at this stage.

What This Means for Your Portfolio

If you hold Braveheart Bio equity as an employee or early investor, your shares remain illiquid for at least 180 days post-IPO. On a $500K position at a 37% ordinary income tax rate (if exercised options), your net proceeds are $315K. If you wait for long-term capital gains treatment at 20%, net proceeds rise to $400K. That is $85K in tax savings, or 27% more cash in hand, purely from holding through the lockup period.

For those without existing exposure, IPO allocations to retail investors are typically under 10% of total shares issued. Priority goes to institutional buyers and the underwriters' client base. Direct access requires a relationship with the lead underwriter or a brokerage platform offering IPO access at the $500K account tier.

Scenario Analysis

Position Size (pre-IPO value)	Tax at Exercise (37% ordinary income)	Tax at Sale (20% long-term capital gains)	Net Benefit of Waiting
$500K	$185K tax / $315K net	$100K tax / $400K net	$85K (27% increase)
$1M	$370K tax / $630K net	$200K tax / $800K net	$170K (27% increase)
$2M	$740K tax / $1.26M net	$400K tax / $1.6M net	$340K (27% increase)

This assumes shares qualify for long-term capital gains treatment. ISO holders with AMT exposure face a different calculation. NSO holders pay ordinary income at exercise regardless of holding period, so immediate sale post-lockup is typically optimal unless the stock appreciates materially.

What to Do With This

If you hold unvested equity, your lockup clock starts at IPO date, not vest date. Accelerated vesting clauses tied to IPO events are common in biotech employment contracts. Review your equity agreement for change-of-control or IPO-triggered acceleration terms. If you have 10,000 unvested shares and the IPO prices at $15, a full acceleration clause puts $150K in your account 180 days earlier than a standard four-year vest.

Biotech IPOs in 2025 traded down an average of 18% in the first 90 days as lockup expiration approached and early investors took profits. Market entry timing depends on individual circumstances and risk tolerance.

Use CalcMoney's Calculate Your After-Tax RSU Proceeds to model your exact position under current tax brackets and lockup scenarios.

The Scenario You Have Not Modelled

Qualified Small Business Stock (QSBS) exclusion under Section 1202 allows up to $10M or 10x cost basis (whichever is greater) in tax-free gains if shares were acquired at original issue and held for five years. If Braveheart Bio was formed after September 27, 2010, and you acquired shares directly from the company, the IPO does not restart your holding period. Your five-year clock continues. On a $2M position that grows to $10M, QSBS saves you $2M in federal capital gains tax. Check your stock certificate or purchase agreement for the issue date and confirm the C-corp election was in place when you received shares.

Frequently Asked Questions

Q: What is the standard lockup period for biotech IPOs?
A: 180 days from IPO date, though some underwriters extend to 270 days for executives and board members.

Q: Can I sell my shares immediately after the IPO if I am not an insider?
A: No. If you hold pre-IPO equity, you are subject to the lockup agreement regardless of employment status at IPO date.

Q: How do I know if my shares qualify for QSBS treatment?
A: Check your stock certificate or purchase agreement for the issue date, confirm the company had under $50M in gross assets at issuance, and verify you acquired shares directly from the company, not a secondary buyer.

Q: What happens if the IPO prices below the last private valuation?
A: Your shares are repriced at IPO valuation. A down-round IPO results in immediate mark-to-market losses for pre-IPO holders, but tax basis remains at original exercise price for options.

Run the Numbers

Use CalcMoney's Calculate Your After-Tax RSU Proceeds to see your exact figures under the current tax threshold and lockup timeline.

Disclaimer: This article is for informational purposes only and does not constitute professional financial, tax, or legal advice. Consult with a qualified tax advisor or financial professional regarding your specific situation.

Run the Numbers: Capital Gains Tax Terminal on CalcMoney — see your exact figures under current market conditions.

Data sourced from SEC EDGAR S-1 Filings (IPO). Rates and thresholds are for informational purposes only. Consult a licensed financial advisor before making mortgage, investment, or tax decisions.

Featured Partner

FIDELITY